drugset / Trial / NCT00481832
Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this trial is to develop an alternative treatment for patients with poor risk non-Hodgkin's lymphoma. This trial uses a combination of high dose chemotherapy with stem cell transplant using the patient's own cells. This is followed with non-myeloablative transplant using stem cells from a related or unrelated donor to try and generate an anti-lymphoma response from the new immune system.
Timeline
- Start
- 2007-01
- Primary completion
- 2014-10-27
- Completion
- 2017-03-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD34+ Cells | Cell therapy | 2e+06 cells/kg | — |
| Subject | Cyclophosphamide | Other / unclassified | 4 g | Intravenous |
| Subject | Etoposide | Small molecule | 60 mg/kg | Intravenous |
| Subject | Etoposide | Small molecule | 2 g | Intravenous |
| Subject | carmustine | Small molecule | — | — |
| Background | ANTILYMPHOCYTE IMMUNOGLOBULIN (HORSE) | Protein / enzyme biologic | 1.5 mg/kg | Intravenous |
| Background | Cyclosporine | Peptide | 5 mg/kg | Oral |
| Background | Methylprednisolone | Other / unclassified | 1 mg/kg | — |
| Background | Mycophenolate Mofetil | Small molecule | 15 mg/kg | Oral |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |
| Background | filgrastim | Protein / enzyme biologic | 10 ug/kg | Subcutaneous |